Millie D. Long, MD, MPH

Learning from Our Mistakes and Making it Right in Practice: Righting Our Wrongs of Post-Hoc Analyses

12/14/2019

Use of Infliximab or Adalimumab in Biologic-Naive Patients With Inflammatory Bowel Disease: Study of Patient Reported Outcomes in IBD Partners

BACKGROUND: We sought to compare Patient-Reported Outcomes Measurement Information System (PROMIS) measures and corticosteroid-free remission in biologic naive individuals with Crohn's di...

Jeffrey Curtis ;

Tim Beukelman ;

Xian Zhang ;

Michael Kappelman , MD;

Millie D. Long , MD, MPH;

Kimberly Weaver ;

12/12/2019

Understanding Gastrointestinal Symptoms in Patients With Concomitant Irritable Bowel Syndrome and Inflammatory Bowel Disease: A Cross-Sectional Study From IBD Partners

1 Campbell University School of Osteopathic Medicine, Lillington, North Carolina, United States; 2 Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel ...

Celeste R. Gracey ;

Wenli Chen ;

Michael Kappelman , MD;

Laura Weisbein ;

Millie D. Long , MD, MPH;

Xian Zhang ;

01/11/2024

Podcast

IBD Drive Time: The Best of Digestive Disease Week Part 2

07/12/2023

Millie D. Long , MD, MPH;

Raymond Cross , MD;

Drs Raymond Cross and Millie Long continue their discussion about the best abstracts on inflammatory bowel disease presented at the Digestive Disease Week conference in May.

Drs Raymond Cross and Millie...

07/12/2023

Advances in Inflammatory Bowel Disease Network

Podcast

IBD Drive Time: The Best of Digestive Disease Week Part 1

07/11/2023

Raymond Cross , MD;

Millie D. Long , MD, MPH;

In the first of two episodes, Drs Millie Long and Raymond Cross discuss their choices of the best abstracts on inflammatory bowel disease from the Digestive Disease Week conference held in May.

In the first of two episodes,...

07/11/2023

Advances in Inflammatory Bowel Disease Network

P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients

BACKGROUND: Urgency, the immediate need to defecate, is common in ulcerative colitis (UC). The frequently used patient reported outcome (PRO)-2 for UC includes only rectal ble...

Millie D. Long , MD, MPH;

Jared Sninsky ;

Edward L. Barnes ;

Xian Zhang ;

12/15/2021

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study

BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...

Stephen B. Hanauer , MD;

Michael Silver ;

Brian G. Feagan ;

Raymond Cross , MD;

David Hudesman , MD;

Douglas Wolf ;

Millie D. Long , MD, MPH;

Subrata Ghosh ;

AnnKatrin Petersen ;

Marc Pondel ;

12/15/2021

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P 1 and S1P ...

Raymond Cross , MD;

Jonathan Calkwood ;

Ashwini Pai ;

Millie D. Long , MD, MPH;

Ayanbola Elegbe ;

James Sheffield ;

Douglas Wolf ;

Adil Javed ;

AnnKatrin Petersen ;

Marc Pondel ;

Lorna Charles ;

Harris A. Ahmad ;

12/15/2021

Podcast

IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis

09/03/2024

Erin Forster , MD, MPH;

Millie D. Long , MD, MPH;

Raymond Cross , MD;

Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.

Dr Erin Forster of the Medical...

09/03/2024

Advances in Inflammatory Bowel Disease Network